Twenty hours. That is what early-access sites report saving per study activation using WCG’s newly launched Activation Intelligence, a figure that matters because it comes from the part of a trial’s life cycle where delays compound fastest. WCG announced the product on October 12, and the number comes from the first two months of use across customers who collectively ran thousands of multi-document queries during that window.
The problem Activation Intelligence targets is structural. Study activation requires teams to reconcile information spread across protocols, consent forms, investigator brochures, contracts, budgets, and operational manuals, and when those documents contradict each other, the consequences show up downstream. Tufts CSDD data from 2022/2024 found that 76% of clinical trial protocols required at least one substantial amendment, up from 57% in 2015, with an average of 3.3 substantial amendments per protocol. Each amendment triggers renegotiation, repeated review, and enrollment delays. WCG’s pitch is that catching the inconsistency before activation is worth more than fixing it afterward.
The tool sits inside WCG’s broader Study Intelligence Hub and was co-developed with one of the nation’s largest academic medical centers, though WCG does not name the institution. An AI assistant lets users pose complex questions across an entire document set and receive answers tied directly to the source material, so pharmacy, laboratory, budgeting, and regulatory teams each get information formatted for their existing workflows rather than a single undifferentiated output. The architecture matters because the failure mode of document-review AI is confident but unsourced answers; the source-verification link is the design choice that addresses that risk, and it also aligns with what the FDA’s January 2025 draft guidance on AI in clinical trials emphasized: transparency into how AI-generated outputs connect to underlying evidence.
WCG is demonstrating Activation Intelligence this week at the Global Site Solutions Summit in Orlando at booth 801. The concrete thing to track is whether that 20-hour savings figure holds as adoption moves beyond early-access customers to sites with less controlled document environments, since that is where inconsistency problems are usually worse and where the tool’s source-verification design will be tested most directly.
Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.
